Sanofi
Pays vs peer median
×1.08
+8% premium
Sample
58
high confidence
Last refreshed
2026-04-13
By therapeutic area
| Therapeutic area | Premium | Deals |
|---|---|---|
| oncology | ×0.82 | 41 |
| immunology | ×1.50 | 5 |
| rareDisease | ×1.50 | 5 |
By stage at signing
| Phase | Premium | Deals |
|---|---|---|
| approved | ×1.50 | 20 |
| phase 2 | ×0.73 | 15 |
| phase 3 | ×0.89 | 11 |
| preclinical | ×1.43 | 5 |
| phase 1 | ×0.76 | 4 |
| discovery | ×0.99 | 3 |
Recent disclosed deals
| Year | Asset | Licensor | Indication | Phase | Upfront | Total |
|---|---|---|---|---|---|---|
| 2026 | rovadicitinib | Sino Biopharmaceutical (Chia Tai Tianqing Pharmaceutical) | myelofibrosis, chronic graft-versus-host disease | approved | $135M | $1.5B |
| 2026 | rovadicitinib | Sino Biopharmaceutical | chronic graft-versus-host disease (cGVHD) | phase_2 | $135M | $1.5B |
| 2025 | Anti-SIRPα-501 | Verve Therapeutics | Mantle Cell Lymphoma | phase_2 | $388M | $2.9B |
| 2025 | mTOR-101 | Relay Therapeutics | Sarcoma | phase_3 | $862M | $5.1B |
| 2025 | ERK-201 | Syros Pharmaceuticals | NSCLC | phase_3 | $851M | $4.2B |
| 2025 | PD-L1 | Zai Lab | Breast (HR+) | phase_3 | $227M | $1.8B |
| 2025 | OX40-101 | G1 Therapeutics | Endometrial | preclinical | $51M | $678M |
| 2025 | MET-mab | Zymeworks | AML | discovery | $18M | $362M |
| 2025 | Anti-KIT-301 | MacroGenics | Prostate | phase_3 | $480M | $3.8B |
| 2025 | CD33 | CytomX Therapeutics | Mantle Cell Lymphoma | preclinical | $90M | $873M |
| 2025 | BRAF V600E-401 | Sumitomo Pharma | AML | discovery | $16M | $232M |
| 2025 | systemic mastocytosis | Blueprint Medicines | systemic mastocytosis | approved | $9.5B | $9.5B |
| 2025 | RET-301 | Fate Therapeutics | Ovarian | phase_1 | $133M | $1.1B |
| 2025 | VG-3927 (TREM2 agonist) | Vigil Neuroscience | Alzheimer's disease | phase_1 | $470M | $600M |
| 2025 | CDK4/6-mab | Replimune | CLL | phase_3 | $856M | $4.4B |
How this is computed
For each Sanofi deal we find the median total deal value of comparable transactions (same therapeutic area + phase, falling back to TA-only with ≥3 peers). The buyer’s deal divided by the peer median is the per-deal premium. We trim outliers, take the trimmed mean, and clamp to [0.7×, 1.5×] to reject data errors. Confidence scales with sample size.
Trimmed mean of 58 disclosed deal premiums vs. peer medians. Raw premium 1.079, clamped to [0.7, 1.5].